Categories
Politics

Congress Rushes to Assist Afghans Searching for Visas for Serving to U.S.

WASHINGTON – As President Biden’s September deadline for ending the long war in Afghanistan draws nearer, a bipartisan coalition in Congress is stepping up efforts to ensure that Afghans who retaliate there for cooperation with American troops and personnel go to the United States can immigrate.

The group of Republicans and Democrats, many of them military or veterans who have worked with translators, drivers and fixers in Afghanistan and other combat areas, are trying to legislate to aid the “Afghan allies,” as they are often called before American forces go home, leaving these allies unprotected against Taliban revenge attacks. Legislators want to make it easier for Afghans to qualify for a special visa, expedite the process and get them out of Afghanistan as soon as possible while they wait to be allowed to live legally in the US.

More than 18,000 Afghans who worked as interpreters, drivers, engineers, security guards and embassy workers for the United States during the war are stuck in a bureaucratic swamp after applying for a special immigrant visa – available to people who work for the government because of their work United States – some wait up to six or seven years for their applications to be processed.

The number of backward cases does not take into account family members, an additional 53,000 people, or the expected increase in requests for the withdrawal of American troops.

“We are frustrated here as lawmakers, especially those of us who have served and want to help the people who have helped us,” said Rep. Brad Wenstrup, Ohio Republican and Army Reserve colonel who served with Iraqi Collaborated with translators in Iraq in 2005 and 2006 as a combat surgeon.

Over the past few weeks, Mr Wenstrup said he had thought of the Iraqis he had served with – people who liked to sell art and pirated copies at the army base – including two killed in surprise attacks near Abu Ghraib and one third who finally got his visa and is now a US citizen and a successful cardiologist in Ohio.

“They will be your brothers and sisters,” he said.

Mr. Wenstrup is part of the Working Group Honoring Our Promises – comprised of 10 Democrats and six Republicans – that spearheaded laws introduced Thursday that would expedite special immigrant visas from Afghanistan, increasing the number available from 11,000 to 19,000. The group is also lobbying the Biden government in an unlikely attempt to initiate a mass evacuation of Afghan applicants, possibly to Guam U.S. territory, while visas can be processed.

The bill would expand the universe of eligible Afghans by removing what its proponents call “onerous” application requirements, including a “credible affidavit” of a particular threat and evidence of a “sensitive and trustworthy” job. Instead, the measure would de facto provide that any Afghan who has helped the US government will, by definition, face retaliation and apply for a visa.

“It became very clear to us that we had very little time left to help the people of Afghanistan,” said Jason Crow, a Democrat from Colorado, law sponsor and former Army Ranger who served in Iraq and Afghanistan Has. “I have very big concerns.”

While Mr Biden set September as the exit date, military officials have since indicated that the schedule has accelerated, with American forces and NATO allies planning to leave by mid-July.

Rep. Michael Waltz, Republican of Florida and former Green Beret who still serves as a colonel in the Army National Guard, said Mr. Biden was short of time to look into the situation.

“If he doesn’t act and doesn’t get these people out, blood will stick to his hands and the hands of his administration,” said Mr Waltz.

The nonprofit No One Left Behind has tracked the murder of more than 300 translators or their family members since 2014, many of whom died while waiting for their visas to be processed, according to James Miervaldis, chairman of the group and sergeant of the Army Reserve.

A death database maintained by the group serves as a catalog of horrors: an interpreter was killed in a suicide attack in front of a bank; another was captured and tortured along the Kandahar-Kabul highway; another was killed in a night attack on his home.

In a poll by the organization, more than 90 percent of the 464 Afghan allies surveyed said they had received at least one death threat because of their work with Americans.

‘They are all generally scared,’ said Mr Miervaldis.

He found that the average time an Afghan applicant waited for a special immigrant visa to be processed was 3.5 years.

“We have people who wait six years, people who wait seven years,” he said. “There is literally no opposition in Congress and it’s frustrating how slow progress is coming.”

A mass evacuation would be a logistical challenge, similar to moving a small town. To date, the Biden government has resisted such calls and the prospect seems very unlikely. In a recent interview on CNN, Foreign Secretary Antony Blinken called evacuation “the wrong word” and instead advocated improving the functioning of the visa program.

He said the Biden government recently hired 50 people to expedite the process.

“We are determined to fulfill our obligation to those who have helped us, who put their lives at risk,” said Blinken. “We have invested significant resources to ensure that the program can work quickly and effectively.”

But the pressure to do more is growing. Last week the New York Times published interviews with Afghan interpreters who said they feared for their lives while they waited for their applications to be processed.

“If the Taliban take power, they will find and kill me easily,” said one man, Waheedullah Rahmani, 27, who has been waiting for a visa decision since 2015. “Then my wife will not have a husband and my daughter will not have a father.”

The special immigrant visa has been plagued by chronic delays and congestion to varying degrees for more than a decade. Mr Crow said the problem was exacerbated by former President Donald J. Trump, who starved the program of resources and personnel, and then by the coronavirus pandemic, which suspended personal interviews and reviews.

In a January report by the Ministry of Foreign Affairs, “limited staffing” and “local security conditions directly related to the Covid-19 pandemic” were cited as “serious” implications for the visa application process.

Mr. Crow and Mr. Wenstrup have taken a number of steps, including this week, to speed up the process. A separate bill they drafted would remove the requirement for Afghan special immigrant visa applicants to undergo medical examinations. There is only one clinic in the country that carries out the examinations – a German facility in Kabul – where some translators have to travel far under sometimes dangerous conditions. And the exams are pretty expensive, said Mr. Crow.

Rep. Adam Kinzinger, Republican from Illinois, and Earl Blumenauer, Democrat from Oregon, have taken another step to increase the number of visas available by 4,000. To date, around 15,000 visas have been approved since the program began, but only around 11,000 are still available – a number that, according to legislators, falls far short of what is needed.

“It was annoying: the dragging with the feet, the lack of coordination,” said Blumenauer. “It was incredibly frustrating. As a country, we have not met our responsibility. “

They found support in the other chamber from Senator Joni Ernst, Republican of Iowa and Lt. Col. Army National Guard, and Senator Jeanne Shaheen, Democrat of New Hampshire. The couple have written to the Biden government asking for 20,000 visas to be added to the program and a resolution to the bureaucratic problems that have caused the backlog.

“We are deeply concerned about the fate of these people after the withdrawal of US troops,” wrote the senators in a letter signed by 18 of their colleagues. “While this would be an increase compared to previous years, it is necessary to do everything in our power to support the program as long as the US has the appropriate capacities in the country.”

Ms. Shaheen last week introduced laws that would expand and modify the Afghan special visa program for immigrants, postpone medical examinations, and extend visas for spouses and children of allies killed while waiting for their visas to be processed.

“Leaders from both parties have shown their support,” said Crow. “I expect we will get expedited handling of these bills.”

The bills have attracted dozens of co-sponsors, and legislators from both parties have given the visa program strong support in the past. In December, under a huge fallback bill, Congress raised the overall visa program ceiling by 4,000 to 26,500.

Several non-profit groups and refugee lawyers are urging the Biden government to do more.

About 70 organizations recently wrote a letter to Mr. Biden urging his government to “immediately implement plans to evacuate vulnerable US-affiliated Afghans.”

Krish O’Mara Vignarajah, president of the Lutheran Immigration and Refugee Service who organized the campaign, points to a precedent in pointing to the 1975 evacuation of 130,000 Vietnamese refugees by the Ford government via Guam to the United States; 1996 Airlift of 6,600 Iraqi Kurds out of the country; and in 1999 the evacuation of 20,000 Kosovar Albanians to Fort Dix, NJ

“We promised them that we would not turn our backs on them and leave them behind,” said Ms. Vignarajah.

Abdul Wahid Forozan, 34, was a translator for the American military in Afghanistan, came to America a year and a half ago through the Visa program, is now married, a father and works as a concierge in College Park.

In an interview, he described the decision to leave Afghanistan as difficult and painful, but said it was his only option given the death threats he faced.

“Home is loved by everyone, nobody dislikes their country,” said Mr Forozan. “But if your life is in danger, if your family’s life is in danger, if you are threatened every day, I couldn’t live in Afghanistan.”

David Zucchino contributed to the coverage.

Categories
Politics

Obamacare survives after Supreme Courtroom rejects newest Republican problem

The Supreme Court ruled 7-2 on Thursday against Texas and other Republican-led states seeking to strike down Obamacare in the law’s latest test before the nation’s highest court.

The court reversed an appeals court ruling that had struck down the law’s individual mandate provision. Chief Justice John Roberts and fellow conservative Justices Clarence Thomas, Brett Kavanaugh and Amy Coney Barrett joined Justice Stephen Breyer’s opinion, as did Sonia Sotomayor and Elena Kagan.

Breyer said Texas and the other states that challenged the law failed to show they were harmed by it.

“Neither the individual nor the state plaintiffs have shown that the injury they will suffer or have suffered is ‘fairly traceable’ to the ‘allegedly unlawful conduct’ of which they complain,” Breyer wrote.

The decision marks the third time that Obamacare, officially known as the Affordable Care Act, has survived a challenge before the Supreme Court since former President Barack Obama signed the landmark legislation into law in 2010.

Defenders of Obamacare worried that the Supreme Court – with its 6-3 majority of Republican-appointed justices – would scrap the law, a crucial element of the nation’s health-care system.

President Joe Biden, who served as Obama’s vice president when the law was signed, praised Thursday’s ruling as a “major victory” for millions of Americans who were at risk of losing their health care in the midst of the Covid pandemic if the law was overturned.

Biden also vowed to expand Obamacare, a central promise of his presidential campaign.

“After more than a decade of attacks on the Affordable Care Act through the Congress and the courts, today’s decision – the third major challenge to the law that the U.S. Supreme Court has rejected – it is time move forward and keep building on this landmark law,” Biden said in a statement.

“Today’s decision affirms that the Affordable Care Act is stronger than ever, delivers for the American people, and gets us closer to fulfilling our moral obligation to ensure that, here in America, health care is a right and not a privilege,” he said.

Obama said the Supreme Court’s ruling makes clear that the law will endure, and the principle of universal health-care coverage has been established.

Two of former President Donald Trump’s Supreme Court picks, Kavanaugh and Barrett, joined the court’s overwhelming majority in rejecting the latest Republican effort to overturn the law. Democrats had warned during Barrett’s confirmation hearings that she was likely to cast a vote in the case that would jeopardize Obamacare.

Justices Samuel Alito and Neil Gorsuch, both conservatives, dissented from the court’s majority opinion.

“Today’s decision is the third installment in our epic Affordable Care Act trilogy, and it follows the same pattern as installments one and two,” Alito wrote in a dissent that was joined by Gorsuch. “In all three episodes, with the Affordable Care Act facing a serious threat, the Court has pulled off an improbable rescue.”

Trump tried unsuccessfully throughout his one term in office to overturn Obamacare. However, Congress as part of the 2017 tax bill effectively eliminated Obamacare’s so-called individual mandate penalties by reducing them to $0.

Texas and more than a dozen other Republican-led states then filed suit, arguing that that change to the law rendered it unconstitutional. The Supreme Court had previously upheld the mandate under Congress’ power to tax, but the GOP-led states argued that the tax justification was no longer valid if the penalty was nonexistent.

Those states, backed by Trump’s Department of Justice, argued that the entire Affordable Care Act should be erased if the individual mandate provision was found to be unlawful.

The case made its way through federal district court and the U.S. Court of Appeals for the Fifth Circuit, which agreed that the individual mandate was unconstitutional. But 20 Democrat-led states, led by California, asked the Supreme Court to reverse the appeals court’s judgment, arguing that with the mandate reduced to zero Americans have the choice whether or not to buy insurance.

The Supreme Court agreed in March 2020 to hear the case.

A spokeswoman for Trump did not immediately respond to CNBC’s request for comment on the court’s ruling.

Numerous Biden administration officials and the top Democrats in Congress were quick to celebrate the decision.

“Each time, in each arena, the Affordable Care Act has prevailed,” Senate Majority Leader Chuck Schumer, D-N.Y., said on the Senate floor minutes after the ruling.

“Let me say definitively: The Affordable Care Act has won, the Supreme Court has ruled, the ACA is here to stay. And now, we’re going to try to make it bigger and better,” Schumer said.

“What a day,” he added.

House Speaker Nancy Pelosi, who was instrumental in the law’s passage, hailed the ruling and praised Obamacare as a “pillar of American health and economic security.”

“Today’s Supreme Court decision is a landmark victory for Democrats’ work to defend protections for people with preexisting conditions,” the California Democrat said during her weekly press conference.

White House chief of staff Ron Klain tweeted “It’s still a BFD” — an apparent reference to Biden’s infamous hot-mic comment at the signing of the bill in 2010, when he whispered to Obama, “this is a big f—— deal.”

“Today is a good day,” tweeted Sabrina Singh, deputy press secretary for Vice President Kamala Harris.

White House communications official Karine Jean-Pierre noted that the ruling marked the third time Obamacare survived a challenge in the high court.

Categories
Politics

U.S. Is Working to Ship Doses Overseas by Changing AstraZeneca Photographs With Others

With less than two weeks left to fulfill President Biden’s promise to share 80 million doses of the coronavirus vaccine with countries in need, production problems at an Emergent BioSolutions manufacturing facility are forcing the government to revise its plan to send AstraZeneca doses overseas .

Officials are now working to replace tens of millions of doses of the AstraZeneca vaccine that were originally intended to be included in the donation with others from Pfizer and BioNTech, Moderna and Johnson & Johnson, according to people familiar with the discussions. These three vaccines are approved in the US for emergency use.

A pattern of serious neglect at the Baltimore facility has challenged the fate of more than 100 million doses of AstraZeneca and Johnson & Johnson vaccines manufactured there. The Food and Drug Administration reviews the records of virtually every batch that Emergent has produced to determine if the cans are safe. The FDA has so far decided that approximately 25 million Johnson & Johnson cans made at the factory can be cleared, but has not made a decision on the AstraZeneca cans.

AstraZeneca’s vaccine is significantly cheaper than the other three vaccines: the federal government paid less than $ 4 per dose, compared to up to $ 19.50 for Pfizer. A administration official said that if the AstraZeneca cans produced by Emergent are declared safe, the supply will ultimately be shared with other nations.

The cans the government plans to ship overseas this month will be part of existing orders from other manufacturers that have not yet shipped to states, said a person familiar with the planning. Ten million doses of the three US-approved vaccines that have already been shipped are unused. According to the Centers for Disease Control and Prevention, over 175 million people in the US have received at least one dose.

Until the White House announced last week it would share 500 million doses of the Pfizer vaccine with the rest of the world, the AstraZeneca doses made up the bulk of the government’s vaccine diplomacy.

Mr Biden pledged to share up to 60 million doses of AstraZeneca’s vaccine with other nations in late April pending the ongoing FDA review of Emergent. In May, the White House announced it would send at least another 20 million doses of other vaccines overseas, bringing the total to 80 million by the end of June.

Earlier this month, the White House stated how it would initially distribute 25 million of the 80 million cans across “a wide range of countries.” Millions of these have already been shipped and more will be shipped shortly, a White House spokesman said.

Jeffrey D. Zients, the White House’s Covid-19 response coordinator, said Thursday that 80 million doses would be allocated by the end of the month but did not specify the type. He said the government was working with other countries on complicated logistical issues, including securing needles, syringes and alcohol swabs that would fit the cans.

“We will allot all of the initial 80 million cans in the coming days and shipments will be sent out as soon as countries are ready to receive the cans,” Mr. Zients said at a press conference. “There will be an increasing number of broadcasts each week as we step up these efforts.”

To share vaccines other than AstraZeneca’s, said a person familiar with the plan, the administration will likely need permission from the manufacturers. These discussions are still going on, said the person.

Categories
Politics

Males charged in shell firm inventory fraud scheme, used SEC filings

Three men have embarked on a brazen scheme to “secretly kidnap” and take over dormant mailbox companies, whose shares they then fraudulently inflated to sell to ignorant investors, according to the indictment, which was unsealed on Friday.

The 2017-2019 men allegedly used fake resignation letters to take control of four mailbox companies, then used the Securities and Exchange Commission’s EDGAR public filing system and fake press releases to fraudulently “pump up” their stock prices by seeking new business opportunities says.

Millions of shares of those stocks, which the defendants bought in many cases for less than 1 cent a share, were then sold over-the-counter by the men and others at gains of up to 900%, according to the court record.

The defendants – Mark Allen Miller, Christopher James Rajkaran and Saeid Jaberian, also known as Andre Jaberian – are charged in 15 cases of securities fraud, securities fraud conspiracy and wire transfer fraud.

The indictment states that Minnesota residents, Miller and Jaberian, as well as an unidentified person who is a relative of Miller, actually became the nominal CEOs and presidents of the companies affected by the scam.

Prosecutors believe the men made hundreds of thousands of dollars in illegal profits just from the behavior described in the indictment, according to a spokeswoman for the US prosecutor in Minnesota.

The indictment, filed in the U.S. District Court in Minnesota, was first reported Friday on the Twitter account of Seamus Hughes, associate director of the Extremism Program at George Washington University.

Hughes regularly scours the federal court’s online archive system, PACER, for interesting criminal and civil litigation documents that were not previously reported.

The Securities and Exchange Commission did not immediately respond when CNBC asked if the agency had taken any action against the defendants and whether they had made changes to the EDGAR file system to prevent tampering by suspected fraudsters.

None of the defendants could be reached for comment.

Rajkaran, a resident of Queens, New York and Guyana, was arrested on Friday as a possible aviation hazard after appearing in court in Brooklyn, New York.

The other two defendants, Miller and Jaberian, are due to appear in federal court in Minnesota on July 2.

The four mailbox companies affected by the alleged conspiracy were Digitiliti, Encompass Holdings, Bell Buckle Holdings, and Utilicraft Aerospace Industries.

While the companies were supposedly doing business – online privacy services, computer software, debt collection, and aerospace – all were actually dormant mailbox companies “with no business or income to speak of,” the indictment said.

The companies had all stopped filing required documents with the SEC and the Secretary of State, but their shares were publicly traded on the over-the-counter market.

After the corporate quartet was identified, “the conspirators then bought shares in the dormant public letterbox companies at low prices on the OTC market,” the indictment said.

“The conspirators were able to buy hundreds of thousands or even millions of shares because the shares traded for a fraction of a penny per share.”

In the Digitiliti case, according to the indictment, Miller drafted a fake resignation letter and board minutes in September 2017, falsely stating that the company’s previous CEO had resigned and Miller had been appointed president and CEO.

Miller then filed with the SEC papers falsely identifying himself as the company’s new head and asked for “the login codes that allow him access to the company’s SEC-EDGAR filing account.”

This in turn “allowed Miller to make public filings with the SEC on behalf of the company.”

The EDGAR system is used by publicly traded companies to disclose material events, including quarterly and annual financial results, changes in management, and sales and purchases of significant amounts of company stock by insiders and others.

The indictment states that Miller bought 50,000 Digitiliti shares in November 2017.

“After Digitiliti’s kidnapping, the Defendant Miller used his control over the company to issue a false and misleading press release on behalf of the company,” the indictment stated.

“On or about July 9, 2018, Miller issued a press release falsely claiming that Digitiliti was ‘negotiating’ with a private company that is trying to ‘buy’ Digitiliti.”

The press release also falsely alleged that the private company “has a proven track record of generating revenue and succeeding in a highly desirable sector of the market,” according to the indictment.

Miller sold his 50,000 Digitiliti shares three weeks later.

During the alleged hijacking of Encompass Holdings from June to November 2017, Miller and Rajkaran together bought more than 40 million shares in the company at low prices, the indictment said.

As with Digitiliti, Miller claimed in a forged letter of resignation and board minutes that he had become president and CEO, the indictment said.

Rajkaran then began posting about the company on investorhub.com to “promote and raise the price of ECMH stock,” the indictment stated.

“For example, he announced that the new CEO is’ likely to have nearly 20 million real estate holdings”[s] and construction machinery … heard, he owns several shopping centers in Mn ‘, “the indictment reads.

Miller then released a press release falsely claiming that Encompass “had signed a letter of intent to acquire approximately $ 6.4 million in assets from DDG Properties. according to the indictment.

“None of that was true.”

The stock price rose in response to the allegations, and Miller shortly thereafter sold 12 million shares in the company at fraudulently inflated prices and made a gain of more than 300%, the indictment said.

Rajkaran achieved an earnings return of around 150% after dumping more than 34 million shares, according to the indictment.

Categories
Politics

The Supreme Court docket’s Latest Justices Produce Some Sudden Outcomes

Justice Alito was aghast. “Today’s decision is the third installment in our epic Affordable Care Act trilogy, and it follows the same pattern as installments one and two,” he wrote, joined by Justice Gorsuch. “In all three episodes, with the Affordable Care Act facing a serious threat, the court has pulled off an improbable rescue.”

Richard J. Lazarus, a law professor at Harvard, said the decisions “suggest that several key justices are willing to temper their views to join the chief’s longstanding battle to have the court decide cases more narrowly and with a more unified voice.”

But he added a note of caution. “What remains to be seen,” he said, “is whether, notwithstanding the chief’s best efforts, his battle to promote a nonpartisan image for the court is ultimately a losing one.”

So far this term, the court’s three Democratic appointees have voted with the majority 73 percent of the time in divided cases, slightly ahead of the 72 percent rate of the six Republican appointees. In the term that ended last year, the gap was 14 percentage points in favor of Republican appointees.

The change may be explained by strategic voting. The court’s Democratic appointees have not hesitated to join unanimous decisions with conservative outcomes, as labeled by the Supreme Court Database at Washington University. The percentage of liberal decisions in unanimous cases so far this term is just 30, the lowest since at least 1953.

But the story changes in divided cases, where 64 percent of decisions have been labeled liberal, the highest since 1968.

“Going into this term,” Professor Epstein said, “the expectation was a bunch of divided decisions with the three Democratic appointees getting the short end of the stick. So far that prediction is way off the mark. In divided cases, the Trump appointees have moved the court to the left. If anyone got the short end of the stick, it’s this year’s most conservative justice, Alito.”

Categories
Politics

With automotive costs surging, yours is a chief goal for thieves

RubberBall Productions | Brand X Pictures | Getty Images

You can blame the Covid pandemic for another thing: an increase in car thefts.

Vehicle thefts in the United States rose 9% year over year to 873,000, the highest number in more than a decade, according to National Insurance Crime Bureau statistics provided by CNBC’s American Greed.

The pandemic created a “perfect storm” of conditions for the increase in car thefts, said NICB President and CEO David Glawe.

“We have a lot of disenfranchised youth who are unemployed and outreach programs are being closed or restricted because of Covid,” he said. “There is frustration and anger in society. We are also seeing restrictions on public safety and the withdrawal of proactive police forces due to budget constraints.”

Vehicles are also particularly valuable these days. Due to the tight supply and strong demand after the pandemic, used car prices have increased by almost 30% compared to the previous year.

The rise in thefts started slowly and coincided with the start of the pandemic in March 2020. They accelerated until last June when the first wave of Covid lockdowns subsided and a second wave loomed. In November, monthly thefts were 18% ahead of 2019.

The biggest jump was in Chicago, where vehicle thefts rose by 134% last year, the NICB said. The Chicago police said the number of carjackings had doubled.

“This has been a year that has presented law enforcement with numerous challenges,” Chicago Police Commissioner David Brown said in a January statement announcing the numbers.

The numbers have leveled off a bit as pandemic restrictions have eased, but Chicago police data released earlier this month shows thefts are still 9% higher than a year ago.

Elsewhere, thefts rose 68% in New York City and 50% in Washington, DC, the NICB said.

Hot goods

Criminals have long understood how lucrative trading in vehicles can be. An extreme example of another type of vehicle crime in 2014 was serial fraudster and internet influencer TR Wright III, who portrayed himself as an arms dealer and an internationally mysterious man.

“All of the Instagram photos showed this person with fancy cars, guns, high-end clothing, high-end vehicles, yachts, jets traveling around the world,” said James Reed, agent for the US Bureau of Alcohol, Tobacco and Firearms, opposite “American Greed.”

Wright, 36, admitted to being part of a conspiracy in which he bought a 2008 Lamborghini Gallardo with a salvage title at a bargain price of $ 76,000, deliberately ditched it, and raised nearly $ 170,000 in insurance revenue.

Wright pleaded guilty to two counts of conspiracy in 2018, in a far-reaching scheme that affected not only vehicles but boats and planes as well. Wright, who is serving a five-year prison sentence, told American Greed that he made even more money than prosecutors claim.

“It depends how you do the math, but if you took a total loss, let’s say somewhere between $ 30 million and $ 40 million,” Wright said.

But also much smaller crooks can kill in other ways on the vehicle market, especially with today’s high prices. There is a free market for most cars and trucks and their parts.

While Wright bought his Lamborghini through a company he controlled, it was remarkably easy for criminals to simply steal vehicles. According to the NICB, more than 10% of the stolen vehicles in 2019 – the last year for which full figures are available – had the keys left inside.

How to thwart the thieves

Since almost all cases lead to an insured event, every policyholder suffers in the form of higher premiums. This is why the NICB urges vehicle owners to protect themselves, especially when the crooks are so active.

Here are some tips, some of which are common sense:

  • Take your keys out of the ignition lock when you park the vehicle, or if your vehicle has a remote control key, keep it with you even if you only get out of the vehicle for a short time.
  • Close your doors and windows and park in a well-lit area.
  • Do not leave valuables or other items that might attract the attention of thieves in your car. This also includes your garage door opener.
  • Consider keeping a picture of your vehicle registration on your phone instead of leaving the actual document in the glove box.
  • Think of installing a car alarm, as well as a kill switch that can immobilize a stolen vehicle.
  • Consider buying a GPS tracker that can help authorities find your vehicle.

You may not own a six-digit Italian sports car, but almost anything you drive is a hot commodity these days.

See social media star TR Wright III lead a brazen plot to fame and fortune fraud and hear his own words from prison. Catch a BRAND NEW episode of “American Greed” on CNBC only on Monday, June 21st at 10pm ET / PT.

Categories
Politics

Excessive Hopes for Johnson & Johnson’s Covid Vaccine Have Fizzled within the U.S.

But manufacturing problems at a factory in Baltimore run by Emergent BioSolutions, Johnson & Johnson’s subcontractor, have had serious consequences for the vaccine. Because of a major production mishap that resulted in a two-month shutdown in operations, Johnson & Johnson has essentially been forced to sit out the brunt of the pandemic in the United States while Pfizer and Moderna, the other federally authorized vaccine makers, provided almost all the nation’s vaccine stock.

Johnson & Johnson has had to throw out the equivalent of 75 million doses, and the regulatory authorities in Canada, South Africa and the European Union also decided to pull back millions more doses made at the Baltimore plant. The company has been able to deliver only one-fourth of the 100 million doses it promised the federal government by the end of this month.

Dr. Anne Zink, Alaska’s chief medical officer, said that in her state, Johnson & Johnson’s shot had become a victim of its own timing. By late February, when it was authorized by the Food and Drug Administration, Alaska had figured out how to get two-dose vaccines to remote areas, leaving the one-shot regimen less crucial than she had initially imagined.

Dr. Clay Marsh, West Virginia’s Covid-19 czar, said that the pause and Johnson & Johnson’s later authorization — more than two months after Pfizer’s and Moderna’s — deprived it of a “halo effect.” By the time West Virginia had an ample supply of all three vaccines, he said, “people started to get this concept that maybe there’s something better about being immunized with Pfizer and Moderna.”

The Johnson & Johnson shot had also suffered from a “social network effect,” said Andrew C. Anderson, a professor of public health at Tulane University who researches vaccine hesitancy. Most Americans who were inoculated in the early months of the vaccine campaign received Moderna and Pfizer shots, and so their friends and family were less likely to deviate and accept a different brand.

In Louisiana, hospitals in the New Orleans area have started offering the Johnson & Johnson shot to people on their way out of the emergency room; the thinking is that people will be more likely to accept the vaccine when a doctor who has treated them asks them to take it. And in Arkansas, where only a third of the population is fully vaccinated, state officials are offering Johnson & Johnson doses to agriculture, manufacturing, wastewater and poultry workers, with gift certificates for hunting and fishing licenses as a reward.

Categories
Politics

Biden unable to succeed in settlement with Turkey’s Erdogan over Russian S-400

Russian S-400 missile battalions participate in tactical training to counter attacks of potential sabotage and reconnaissance groups. 

Vitaly Nevar | TASS via Getty Images

WASHINGTON – The Biden administration was unable to work out a resolution with Turkey following Ankara’s defiant purchase of a Russian weapons system, which the NATO alliance views as a security risk.

National security advisor Jake Sullivan told reporters Thursday on a call that President Joe Biden and Turkish President Recep Tayyip Erdogan discussed the 2017 multibillion-dollar weapons deal with Russia this week at NATO’s headquarters.

In December, the Trump administration slapped sanctions on Turkey, a NATO member, for buying the S-400 missile system in a confrontation not typically seen within the alliance.

“On the S-400, they discussed it. There was not a resolution of the issue. There was a commitment to continue the dialogue on the S-400,” Sullivan said, adding the Biden administration would have more to say on the matter after Washington and Ankara hold additional talks.

Turkish President Recep Tayyip Erdogan (L) and US President Joe Biden (R) hold a meeting at the NATO summit at the North Atlantic Treaty Organization (NATO) headquarters in Brussels, on June 14, 2021.

Murat Cetinmuhurdar | Anadolu Agency | Getty Images

During a NATO news conference, Erdogan said he had not changed his position on the S-400 despite having a “sincere” meeting with Biden.

Biden also said the meeting with Erdogan was productive, adding he was confident the U.S. will “make real progress with Turkey.”

Erdogan said Thursday that he told Biden to “not expect Turkey to take a different step on the F-35 and S-400 issues,” according to a report from Turkey’s state media.

“We must monitor developments closely. We will be following up on all our rights,” he said. “In the next period, our foreign ministers, defense ministers and defense industry chairs will be moving this process forward by meeting with their counterparts,” Erdogan added.

In multiple efforts to deter Turkey from buying Russia’s S-400 missile system, the State Department offered in 2013 and 2017 to sell the country Raytheon’s Patriot missile system. Ankara passed on the Patriot both times because the U.S. declined to provide a transfer of the system’s sensitive missile technology.

A F-35 fighter jet is seen as Turkey takes delivery of its first F-35 fighter jet with a ceremony at the Lockheed Martin in Forth Worth, Texas, United States on June 21, 2018.

Atilgan Ozdil | Anadolu Agency | Getty Images

Under the Countering America’s Adversaries Through Sanctions Act any foreign government working with the Russian defense sector will find itself in the crosshairs of U.S. economic sanctions.

Despite warnings from the United States and other NATO allies, Turkey accepted the first of four S-400 missile batteries from the Kremlin in July 2019.

A week later, the U.S. cut Turkey, a financial and manufacturing partner, from the F-35 program.

Due to Turkey’s removal from the F-35 program, U.S. defense giant Lockheed Martin offered the jets originally slated to join Ankara’s arsenal to other customers.

Correction: Erdogan said Thursday that he told Biden to “not expect Turkey to take a different step on the F-35 and S-400 issues,” according to a report from Turkey’s state media. An earlier version misstated the day.

Categories
Politics

A Tablet to Deal with Covid-19? The U.S. Is Betting on It.

The U.S. government spent more than $ 18 billion last year funding drug manufacturers to produce a Covid vaccine, an effort that resulted in at least five highly effective vaccinations in record time. Now, more than $ 3 billion is pouring into a neglected area of ​​research: developing pills to fight the virus at an early stage of infection that may save many lives in the years to come.

The new program, announced by the Ministry of Health on Thursday, will accelerate clinical trials of some promising drug candidates. If all goes well, some of those first pills could be ready by the end of the year. The Pandemic Antiviral Program will also support research into entirely new drugs – not just for the coronavirus, but for viruses that could cause future pandemics.

A number of other viruses, including influenza, HIV, and hepatitis C, can be treated with a simple pill. But despite more than a year of research, there isn’t a pill like this to treat someone with coronavirus infection before it wreaks havoc. Operation Warp Speed, the Trump administration’s program to accelerate Covid-19 research, has invested far more money in vaccine development than in treatments, a void the new program will seek to fill.

Dr. Anthony Fauci, the director of the National Institute of Allergies and Infectious Diseases and a key supporter of the program, said he was looking forward to a time when Covid-19 patients could pick up antiviral pills from a pharmacy once they test positive for that Coronavirus or develop Covid-19 symptoms.

“I wake up in the morning, I don’t feel very well, my sense of smell and taste goes away, I get a sore throat,” said Dr. Fauci in an interview. “I call my doctor and say, ‘I have Covid and I need a prescription.'”

Dr. Fauci’s support for antiviral pill research stems from his own experience fighting AIDS three decades ago. In the 1990s, his institute conducted research that led to some of the first antiviral pills for HIV, “protease inhibitors,” which can block an essential viral protein and keep the virus in check for life.

In the early 2000s, researchers found that an antiviral agent called sofosbuvir could cure hepatitis C nearly 100 percent of the time. Tamiflu, an over-the-counter influenza pill, can reduce recovery time from infection and reduce the chance that a flu attack will bring someone to the hospital.

At the beginning of the pandemic, researchers began testing existing antivirals in people hospitalized with severe Covid-19. But many of these studies showed no benefit from the antiviral drugs. In hindsight, the decision to work in hospitals was a mistake. Scientists now know that the best time to try to block the coronavirus is in the early days of the illness, when the virus is multiplying rapidly and the immune system has not yet built a defense.

Many people fight their infection and recover, but others have immune systems failing and starting to damage tissues instead of viruses. It is this self-inflicted damage that sends many people with Covid-19 to the hospital as the replication of the coronavirus wears off. So a drug that blocks replication early in an infection could very well fail in a study in patients who have advanced into later stages of the disease.

So far, only one antiviral has shown clear benefit for people in hospitals: remdesivir. Originally studied as a potential cure for Ebola, the drug appears to shorten the course of Covid-19 when given intravenously to patients. In October, it became the first – and so far only – antiviral drug to receive full FDA approval for the treatment of the disease.

However, remdesivir’s performance has overwhelmed many researchers. In November, the World Health Organization recommended not using the drug.

Remdesivir could work more effectively if people could take it earlier as a pill in the course of Covid-19. But in its approved formulation, the compound does not act orally. It cannot survive the passage from the mouth via the stomach to the circulatory system.

Researchers around the world are testing other antivirals that are already known to work in tablet form. One such compound called molnupiravir was developed by researchers at Emory University in 2019 and tested against viruses such as influenza and the Venezuelan equine encephalitis virus.

Working with Miami-based Ridgeback Biotherapeutics, the Emory team conducted experiments on mice that were so impressive that Merck turned to them to help bring the drug into human clinical trials for Covid-19.

“We found this molecule really amazing,” said Daria Hazuda, vice president of infectious diseases and vaccine research at Merck.

However, in a study of hospitalized patients, molnupiravir did not appear to have any effect on the disease. In April, the companies announced that they would end the process.

“I see that and I say, ‘Yes, no,'” said Dr. Tim Sheahan, a virologist at the University of North Carolina. “I’m not surprised that these types of drugs would not dramatically improve the outcome of a person who has been sick for several days.”

The companies started a second study last fall, this time testing the drug on people recently diagnosed with Covid-19. This study is ongoing and Merck is recruiting volunteers at higher risk of infection, such as the elderly with obesity and diabetes. Dr. Hazuda said the study should produce clear results by October.

Last year, government funding for Covid-19 treatments focused on a handful of candidates such as monoclonal antibodies and remdesivir. Many other antiviral drug studies have been small and underfunded. In January, the new government of Biden began developing a new program of antiviral pills.

The first results of this planning could be seen last week. The Department of Health and Human Services announced that it will purchase 1.7 million doses of molnupiravir from Merck for $ 1.2 billion, provided the current study leads to Food and Drug Administration approval. According to Dr. David Kessler, the chief science officer of the Biden government’s Covid-19 response team, the government could seek similar deals for two other antivirals in clinical trials.

The hope “is that by the end of the fall we will have an antiviral that can help us close this chapter of the epidemic,” said Dr. Kessler in an interview.

One of the drugs the government is considering is AT-527, which was developed by Atea Pharmaceuticals. The compound has already been shown to be safe and effective for treating hepatitis C, and early studies suggested it could work against Covid-19 as well. Roche has partnered with Atea to test it in humans, and the companies are currently conducting a late-stage clinical trial.

The other drug on government radar was developed by scientists at Pfizer, adapted from a molecule originally developed as a potential drug for SARS in the early 2000s. This drug was on the shelf for years, but last spring scientists decided to change its structure so that it works against the protease of the new coronavirus. More than 200 Pfizer researchers have teamed up to develop the molecule, initially known as PF-07321332.

The drug was intended for intravenous use, but Pfizer researchers managed to modify its structure so that it works as a pill. When the drug was given orally to mice, it reached a concentration high enough in the body to block the coronavirus. Pfizer started a clinical trial in March to evaluate its safety in humans and expects to move to a later stage of testing next month.

Dr. Kessler acknowledged that there will be challenges in using such pills to reduce hospital stays and deaths from Covid-19. People need access to the drugs once they test positive. “Your testing programs need to be linked to your treatment,” he said.

And if the history of antiviral research is any clue, the first drugs for Covid-19 will likely offer only modest benefits against the disease, said Dr. Fauci. But that would be a good start.

“With all of these drugs we’ve looked at over the years, we’ve never landed a home run the first time,” said Dr. Fauci. “A line drive from the left field wall to the start would be really good.”

The government will also spend up to $ 1.2 billion on research centers where scientists will conduct early-stage studies on drugs that block the coronavirus in other ways. Some drugs can interfere with other essential virus proteins, while others make it impossible to copy the virus’ genes.

Even if the next generation of pills won’t hit the market for a few years, many scientists say research will be a good investment. “It could help with this pandemic and potentially be a first line of defense for the next,” said Mark Namchuk, director of therapeutic translation at Harvard Medical School.

The program will not only support research into pills that work against coronaviruses, but also against other high-risk pathogens like flaviviruses, which cause diseases like dengue and West Nile fever, and togaviruses, the mosquito-borne diseases like chikungunya cause and Eastern equine encephalitis.

“There will always be a threat,” said Dr. Fauci. “I think there will be a long-term need for drugs.”

Categories
Politics

Juneteenth turns into federal vacation after Biden indicators invoice

President Joe Biden signed law Thursday introducing Juniteenth, the date to commemorate the end of slavery in the United States, as a federal holiday.

Biden signed the bill two days before June 15 himself, which is June 19 each year, in what he called “one of the greatest honors” of his presidency.

“We have come a long way and we still have to go a long way. But today is a day of celebration,” said Vice President Kamala Harris, who addressed the president at the signing ceremony at the White House.

“Big nations don’t ignore their most painful moments,” Biden told the crowd in the East Room, which included dozens of politicians, activists and community leaders. “You hug her.”

United States President Joe Biden applauds Vice President Kamala Harris as they arrive in the East Room of the White House in Washington on June 17, 2021 to sign the National Independence Day Act of June 2021.

Carlos Barria | Reuters

“In short, this day doesn’t just celebrate the past. He calls for action today, ”said Biden.

National Independence Day in June will be the 12th public holiday, including Inauguration Day, and the first new day since then-President Ronald Reagan signed Martin Luther King Jr. Day in 1983.

Juneteenth celebrates the emancipation of the last of the enslaved African Americans. On that day in 1865, Union soldiers, led by General Gordon Granger, arrived in the coastal city of Galveston, Texas to deliver General Order No. 3 that officially ended slavery in the state.

The final act of liberation came months after the Confederate Army’s surrender ended the Civil War and more than two years after President Abraham Lincoln issued the Emancipation Proclamation.

Lincoln was assassinated on April 15, 1865, two months before his proclamation reached Texas.

Most federal workers will be celebrating June 10th on Friday this year because June 19th falls on a Saturday. The New York Stock Exchange won’t close for June thenth this year, but it will evaluate the closing markets for the holiday in 2022, according to the exchange.

The Securities Exchange Commission will close its offices on Friday for the new holiday, a spokesman said. The SEC’s online data platform, EDGAR, “will also be closed and will not accept filings or assist in assisting applicants,” the spokesman said.

The Holiday Bill was passed with overwhelming support in both houses of Congress this week. The Senate unanimously approved the bill Tuesday night, and the House of Representatives passed it by 415 votes to 14. The only votes against the law came from the Republicans.

Prior to the House vote, some GOP lawmakers complained about the name of the holiday and others expressed concern about the cost of another federal workforce day off. Some also railed against the Democrats for putting the bill to the vote without first allowing the committees to review the law and propose changes.

Still, most of the House Republicans, even those who opposed parts of the bill, voted in favor.

The Juniteenth Bill was sponsored in the Senate by Edward Markey, D-Mass, and the House version, sponsored by Rep. Sheila Jackson Lee, D-Texas, was endorsed by 166 legislators.

The 14 votes against were:

  • Rep Mo Brooks, R-Ala.
  • Rep Andy Biggs, R-Ariz.
  • Rep. Scott DesJarlais, R-Tenn.
  • Rep Tom Tiffany, R-Wis.
  • Rep. Doug LaMalfa, R-Calif.
  • Rep. Mike Rogers, R-Ala.
  • Rep. Ralph Norman, RS.C.
  • Rep. Chip Roy, R-Texas
  • Rep. Paul Gosar, R-Ariz.
  • Rep. Tom McClintock, R-Calif.
  • Rep Matt Rosendale, R-Mont.
  • Rep Ronny Jackson, R-Texas
  • Rep. Thomas Massie, R-Ky.
  • Rep. Andrew Clyde, R-Ga.

– CNBC’s Bob Pisani contributed to this report